GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Accounts Payable & Accrued Expense
Switch to:

Biogen (BUE:BIIB) Accounts Payable & Accrued Expense

: ARS558,612 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's quarterly accounts payable & accrued expense declined from Sep. 2022 (ARS502,012 Mil) to Dec. 2022 (ARS482,363 Mil) but then increased from Dec. 2022 (ARS482,363 Mil) to Mar. 2023 (ARS558,612 Mil).

Biogen's annual accounts payable & accrued expense increased from Dec. 2020 (ARS262,605 Mil) to Dec. 2021 (ARS298,324 Mil) and increased from Dec. 2021 (ARS298,324 Mil) to Dec. 2022 (ARS482,363 Mil).


Biogen Accounts Payable & Accrued Expense Historical Data

The historical data trend for Biogen's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Payable & Accrued Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112,145.99 182,440.98 262,605.11 298,324.45 482,362.57

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Accounts Payable & Accrued Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 294,253.12 449,637.12 502,012.45 482,362.57 558,612.15

Biogen Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Biogen (BUE:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines